Baillie Gifford & Co. Cuts Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Baillie Gifford & Co. trimmed its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 5.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 25,239,870 shares of the company’s stock after selling 1,350,066 shares during the period. Baillie Gifford & Co. owned about 8.98% of Recursion Pharmaceuticals worth $166,331,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC purchased a new stake in Recursion Pharmaceuticals in the third quarter worth $25,000. Farther Finance Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after purchasing an additional 4,091 shares during the period. GAMMA Investing LLC lifted its position in shares of Recursion Pharmaceuticals by 1,588.4% during the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after acquiring an additional 6,036 shares in the last quarter. Amalgamated Bank boosted its holdings in shares of Recursion Pharmaceuticals by 52.4% in the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after acquiring an additional 2,459 shares during the period. Finally, San Luis Wealth Advisors LLC purchased a new position in shares of Recursion Pharmaceuticals in the third quarter valued at $69,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, November 7th. Leerink Partners reduced their price target on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday, September 3rd. Finally, Jefferies Financial Group decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Tuesday, September 3rd. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $9.40.

Insiders Place Their Bets

In other news, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $7.12, for a total transaction of $81,502.64. Following the completion of the transaction, the director now directly owns 7,132,769 shares of the company’s stock, valued at approximately $50,785,315.28. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 6,000 shares of the firm’s stock in a transaction dated Thursday, October 24th. The shares were sold at an average price of $6.31, for a total value of $37,860.00. Following the completion of the sale, the chief operating officer now directly owns 521,138 shares in the company, valued at $3,288,380.78. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Blake Borgeson sold 11,447 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $7.12, for a total value of $81,502.64. Following the transaction, the director now owns 7,132,769 shares in the company, valued at $50,785,315.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 156,682 shares of company stock valued at $1,012,618 in the last quarter. Insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX opened at $7.84 on Tuesday. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of -5.12 and a beta of 0.81. The company has a 50-day simple moving average of $6.58 and a two-hundred day simple moving average of $7.62. The company has a quick ratio of 6.07, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.22 and a 12-month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the business posted ($0.43) EPS. The firm’s revenue for the quarter was up 147.6% on a year-over-year basis. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.54 EPS for the current year.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.